CD44 and neoplasm: Immunohistochemical staining (Figure 2) revealed that increasing proportions of CD44-, ALDH-, and EpCAM-positive CSCs in tumor tissue from oxaliplatin-treated s.c. tumor mice compared with GS-treated s.c. tumor mice.